- Home
- KROS vs CUE Comparison
KROS vs CUE Comparison
Compare KROS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | CUE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 233.5M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KROS | CUE |
|---|---|---|
| Price | $11.43 | $24.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $21.86 | ★ $120.00 |
| AVG Volume (30 Days) | 156.2K | ★ 351.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $243,864,000.00 | $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,751.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $9.69 | $0.17 |
| 52 Week High | $22.55 | $45.50 |
Technical Indicators
Market Signals| Indicator | KROS | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 41.16 |
| Support Level | $10.59 | $23.51 |
| Resistance Level | $11.69 | $33.11 |
| Average True Range (ATR) | 0.43 | 5.01 |
| MACD | 0.00 | -0.64 |
| Stochastic Oscillator | 54.07 | 6.50 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.